Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(1.80)
# 2,940
Out of 4,829 analysts
48
Total ratings
27.66%
Success rate
-5.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $21.71 | +360.62% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.17 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $10.98 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.41 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $11.90 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.17 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $1.60 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $7.17 | - | 1 | Oct 18, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $19.61 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $4.52 | - | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.70 | +35.14% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.98 | +1,226.40% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $7.46 | +7.24% | 1 | Mar 20, 2023 |
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $21.71
Upside: +360.62%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.17
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.98
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.41
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.90
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.17
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.60
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.17
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $19.61
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.52
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.70
Upside: +35.14%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $0.98
Upside: +1,226.40%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $7.46
Upside: +7.24%